RxDoctor Payments Data

Joseph Racanelli, MD

Internal Medicine · New York, NYNPI 1609883776

Payments from drug & device makers

$18,346in general payments, 2019–2025

Across 393 payments — averaging $46.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$4K
  • Intra-sana Laboratories$2K
  • AstraZeneca$2K
  • AbbVie$2K
  • Xeris Pharmaceuticals, Inc.$993
  • Kowa Pharmaceuticals America, Inc.$742
  • plus $8K from 34 others

What the payments were for

  • Food & beverage$18,25299%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,346 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$134,852
Medicare patients
134
Services billed
1,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide24$46,809
XareltoRivaroxaban42$41,512
EliquisApixaban37$37,200
JardianceEmpagliflozin22$31,492
Repatha SureclickEvolocumab33$31,429
MounjaroTirzepatide26$29,011
VascepaIcosapent Ethyl39$24,142
FarxigaDapagliflozin Propanediol28$24,095
TradjentaLinagliptin21$21,027
LinzessLinaclotide23$17,035
GemtesaVibegron15$7,531
SynthroidLevothyroxine Sodium65$7,255
Repatha SyringeEvolocumab14$7,093
Rosuvastatin Calcium284$3,855
Levemir FlexpenInsulin Detemir12$2,689

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$3,660$52,51843 claims
Johnson & JohnsonXarelto$178$41,51242 claims
PfizerEliquis$541$37,20037 claims
Lilly USA, LLCMounjaro$530$29,01126 claims
AbbVieLinzess, Synthroid$1,581$24,29088 claims
AstraZenecaFarxiga$1,637$24,09528 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$24$86964 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →